Levi & Korsinsky Urges Marex Group plc (MRX) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your Marex Group plc (NASDAQ:MRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marex-group-plc-lawsuit-submission-form?prid=176199&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or […]

ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

(NASDAQ:MLTX), NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

(NASDAQ:EVAX), New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01's already strong data package COPENHAGEN, Denmark, November 7, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”),

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 GlobeNewswire November 07, 2025 New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further

ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX GlobeNewswire November 07, 2025 NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10,

WPP Investors Have Opportunity to Lead WPP plc Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased WPP plc

CBSA in British Columbia opens multiple immigration investigations and removes three individuals

The Canada Border Services Agency (CBSA) Pacific Region Immigration Enforcement and Intelligence and Investigations Operations are part of a newly created BC Extortion Task Force which was announced by the Province of B.C. in September and is led by the Royal Canadian Mounted Police (RCMP). This task force was created to address the sharp rise

VFC Deadline: VFC Investors have Opportunity to Lead V.F. Corporation Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities ofV.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”), of the important November 12, 2025 lead plaintiff deadline. https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg So what: If you purchased V.F. Corporation securitiesduring the Class Period you may

NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025

https://mma.prnewswire.com/media/2817292/New_Pacific_Metals_Corp__NEW_PACIFIC_REPORTS_FINANCIAL_RESULTS_F.jpg New Pacific Metals Corp. (“New Pacific” or the “Company”) reports its financial results for the three months ended September 30, 2025. All figures are expressed in US dollars unless otherwise stated. FISCAL 2026 Q1 HIGHLIGHT — The Company closed a bought deal financing on October 21, 2025. A total of 11,385,000 common shares of

Scroll to Top